ImmunityBio company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

immunitybio.com

Founded Year

2014

Stage

Reverse Merger | IPO

Total Raised

$301.59M

About ImmunityBio

ImmunityBio is an immunotherapy company with a broad portfolio of biological molecules spanning albumin-linked chemotherapeutic, peptide, fusion protein, cytokine, monoclonal antibody, adenovirus and yeast vaccine therapies. This platform of technologies has enabled ImmunityBio to achieve late-stage clinical pipelines addressing both the innate (activated macrophage and natural killer cell) and the adaptive immune system (dendritic, CD4 and CD8 killer T cells). The pipeline constitutes over 40 immunological assets with 13 first in human immunotherapy molecules in active clinical trials.

ImmunityBio Headquarters Location

9920 Jefferson Blvd

Culver City, California, 90232,

United States

310-883-1300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ImmunityBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ImmunityBio is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,795 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

ImmunityBio Patents

ImmunityBio has filed 32 patents.

The 3 most popular patent topics include:

  • Immunology
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/27/2020

6/21/2022

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors

Grant

Application Date

2/27/2020

Grant Date

6/21/2022

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Transcription factors

Status

Grant

Latest ImmunityBio News

11:30 EDT Pancreatic Cancer Market to Progress at a CAGR of 7.3 % by 2032 | DelveInsight

Aug 1, 2022

| DelveInsight News provided by Share this article Share this article The pancreatic cancer market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medicine development. LAS VEGAS, Aug. 1, 2022 /PRNewswire/ -- DelveInsight's Pancreatic Cancer Market Insights  report includes a comprehensive understanding of current treatment practices, pancreatic cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan. Key Takeaways from the Pancreatic Cancer Market Report As per DelveInsight analysis, the pancreatic cancer market size in the 7MM was approximately USD 1,649 million in 2021. As per the estimates, the total incident cases of pancreatic cancer were approx 175K in the 7MM in 2021. Leading pancreatic cancer companies such as AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others are developing novel pancreatic cancer drugs that can be available in the pancreatic cancer market in the upcoming years. The pancreatic cancer therapies in the pipeline include Motixafortide, Mitazalimab,  BPX-601, Tedopi (OSE2101), AZD5305,  Elraglusib (9 ING 41),  NT-I7 (Efineptakin Alfa),  Olaptesed pegol (NOX-A12),  siG12D LODER, Sotorasib (LUMAKRAS/AMG 510),  NGM120, Zenocutuzumab (Zeno, MCLA-128),  Adagrasib (MRTX849), RX-3117, Anktiva (N-803), BPM31510 (ubidecarenone), Zejula (niraparib), Glufosfamide, LOAd703 (delolimogene mupadenorepvec), Pamrevlumab, GVAX Pancreatic Tumor Vaccine, and others. The pancreatic cancer market is expected to grow due to factors like an increase in the patient pool and the expected launch of novel emerging therapies. Discover more about therapies set to grab major pancreatic cancer market share @  Pancreatic Cancer Research Pancreatic Cancer Overview Pancreatic cancer develops in the tissues of the pancreas, an organ in the abdomen located behind the bottom portion of the stomach. The pancreas produces hormones that assist control blood sugar and release enzymes that promote digestion. Pancreatic cancer is a disorder in which malignant (cancer) cells originate in pancreatic tissues. The pancreas can grow in various ways, including malignant and noncancerous tumors. However, the exact pancreatic cancer causes are unknown. The average life expectancy of pancreatic cancer for individuals who are diagnosed before the tumor develops or spreads is 3 to 3.5 years. Pancreatic cancer symptoms may include jaundice, dark urine, weight loss, loss of appetite, weariness, and others. The pancreatic cancer diagnosis is difficult as the symptoms are frequently confused with those of other disorders, such as irritable bowel syndrome. Pancreatic cancer treatment options are determined by the degree of cancer. Options may include surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these. Learn more about the diseases and pancreatic cancer diet @ Pancreatic Cancer Tests Pancreatic Cancer Epidemiology Segmentation Among the EU5 countries, Germany had the highest incident cases of pancreatic cancer in 2021. The pancreatic cancer market report  proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Incident Cases of Pancreatic Cancer Molecular Alteration-specific Incident Cases of Pancreatic Cancer Stage-specific Incident Cases of Pancreatic Cancer Download the report to understand which factors are driving pancreatic cancer epidemiology trends @ Pancreatic Cancer Epidemiological Insights Pancreatic Cancer Treatment Market  Surgical treatment is preferred for patients whose disease has been identified as localized or regional. Aside from surgery, chemotherapy is the most popular pharmaceutical pancreatic cancer treatment option. It is preferred for pancreatic cancer patients in all situations. Gemcitabine-based chemotherapeutic regimens are favored over 5-FU-based and other regimens in first-line therapy due to fewer side effects associated with gemcitabine compared to 5-FU-based treatment choices. Gemcitabine + nab-paclitaxel can be used as second-line therapy for individuals who meet certain criteria and have had first-line FOLFIRINOX. In the second-line scenario, monotherapy with GEM or 5-FU is possible for patients with a somewhat low-performance status (ECOG 2), those with medical comorbidities, or elderly patients. Moreover, research and development activities for early detection methods, as well as identifying and developing a potential molecule that can be efficiently used for treating pancreatic cancer patients while imparting the least adverse events, are ongoing in the scientific community. The approval of any upcoming entities currently being evaluated in various clinical phases will significantly alter the treatment landscape for pancreatic cancer patients in the coming years. To know more about pancreatic cancer treatment options, visit @ Pancreatic Cancer Prevention Pancreatic Cancer Pipeline Therapies and Key Companies Motixafortide (BL-8040): BioLineRx/Merck Sharp & Dohme Mitazalimab (ADC-1013): Alligator Bioscience Pamrevlumab (FG-3019): FibroGen siG12D LODER: Silenseed Ltd Anktiva (N-803): ImmunityBio Glufosfamide: Eleison Pharmaceuticals/Molecular Templates CAN04 (Nadunolimab): Cantargia AB As the number of instances of pancreatic cancer rises, so does the pancreatic cancer market size. With the advent of genomic profiling technology and selective molecular targeted medicines, biomarkers have become increasingly significant in the clinical management of pancreatic cancer patients. Moreover, survival in pancreatic cancer patients is constantly improving, indicating that a better understanding of tumor pathobiology will lead to better therapies and outcomes in the pancreatic cancer market. Furthermore, due to a dearth of randomized neoadjuvant trials, research into the use of newer and more aggressive systemic regimens in the neoadjuvant setting to treat PDAC could potentially enhance outcomes in the pancreatic cancer market. Agents targeting the four most prevalent mutations in pancreatic cancer, KRAS, TP53, CDKN2A, and SMAD4, are still in clinical trials, and after the launch, they will change the pancreatic cancer market dynamics. However, several factors are limiting the growth of the pancreatic cancer market. PDAC is a complicated disease with high intra-tumoral heterogeneity and a thick, desmoplastic stroma that might restrict drug delivery to the tumor. Furthermore, it foreshadows an exceedingly intricate interplay of intercellular signals, making in vitro disease research difficult. Because of the genetic mutation diversity and dense connective tissue that forms the pancreas, PDAC is one of the most chemo-resistant types of cancer. Moreover, the advent of generics in the pancreatic cancer market, the expiration of patent protection for certain medications, higher healthcare costs, and a sense of nihilism in patients are all major risks to the pancreatic cancer market. Furthermore, drug development in pancreatic cancer is difficult. Pancreatic cancer has the lowest overall success rate of any solid tumor, at around 10%, which is the primary aspect hindering the growth of the pancreatic cancer market. Scope of the Pancreatic Cancer Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others Key Pancreatic Cancer Therapies: Motixafortide, Mitazalimab,  BPX-601, Tedopi (OSE2101), AZD5305,  Elraglusib (9 ING 41),  NT-I7 (Efineptakin Alfa),  Olaptesed pegol (NOX-A12),  siG12D LODER, Sotorasib (LUMAKRAS/AMG 510),  NGM120, Zenocutuzumab (Zeno, MCLA-128),  Adagrasib (MRTX849), RX-3117, Anktiva (N-803), BPM31510 (ubidecarenone), Zejula (niraparib), Glufosfamide, LOAd703 (delolimogene mupadenorepvec), GVAX Pancreatic Tumor Vaccine, and others Therapeutic Assessment: Pancreatic Cancer current marketed and emerging therapies Pancreatic Cancer Market Dynamics:  Pancreatic Cancer market drivers and barriers  Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Pancreatic Cancer Market Access and Reimbursement Table of Contents

ImmunityBio Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ImmunityBio Rank

  • When was ImmunityBio founded?

    ImmunityBio was founded in 2014.

  • Where is ImmunityBio's headquarters?

    ImmunityBio's headquarters is located at 9920 Jefferson Blvd, Culver City.

  • What is ImmunityBio's latest funding round?

    ImmunityBio's latest funding round is Reverse Merger.

  • How much did ImmunityBio raise?

    ImmunityBio raised a total of $301.59M.

  • Who are the investors of ImmunityBio?

    Investors of ImmunityBio include NantKwest and Celgene.

  • Who are ImmunityBio's competitors?

    Competitors of ImmunityBio include Prokarium.

You May Also Like

Prokarium Logo
Prokarium

Prokarium is a biopharmaceutical company focused on developing vaccination and cancer immunotherapy solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. Prokarium's vision is that all protein vaccines can be delivered orally.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.